DNA Synthesis Market Size, Share & Trends Report

DNA Synthesis Market Size, Share & Trends Analysis Report By Service Type (Gene Synthesis, Oligonucleotide Synthesis), By Length, By Application (Research Development, Diagnostics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68040-009-7
Number of Report Pages: 120
Format: PDF, Horizon Databook

Historical Range: 2018 - 2023
Forecast Period: 2024 - 2030
Industry: Healthcare

Market Segmentation

DNA Synthesis Service Type Outlook (Revenue, USD Million, 2018 - 2030)
- Oligonucleotide Synthesis
  - Standard oligonucleotide synthesis
  - Custom oligonucleotide synthesis
- Gene Synthesis
  - Custom gene synthesis
  - Gene library synthesis
DNA Synthesis Length Outlook (Revenue, USD Million, 2018 - 2030)
- Oligonucleotide Synthesis
  - Less than 50 nt
  - 51-100 nt
  - 101-150 nt
  - More than 150 nt
- Gene Synthesis
  - Less than 500 nt
  - 501-1000 nt
  - 1001-1500 nt
  - 1501-2000 nt
  - 2001-2500 nt
  - More than 2500 nt
DNA Synthesis Application Outlook (Revenue, USD Million, 2018 - 2030)
- Research and Development
  - Oligonucleotide Synthesis
    - PCR
    - NGS
    - CRISPR
    - Cloning and Mutagenesis
    - Others
  - Gene Synthesis
    - Synthetic Biology
    - Vaccine Development
    - Genetic Engineering
    - Others
- Diagnostics
- Therapeutics
  - RNAi Therapies
  - Antisense Oligonucleotide-based Therapies
  - Others
DNA Synthesis End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Biopharmaceutical and Diagnostics Companies
- Academic and Research Institutes
- Contract Research Organizations
DNA Synthesis Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Service Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
    - Standard oligonucleotide synthesis
    - Custom oligonucleotide synthesis
    - Gene Synthesis
    - Custom gene synthesis
    - Gene library synthesis
  - North America Length Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
      - Less than 50 nt
      - 51-100 nt
      - 101-150 nt
      - More than 150 nt
    - Gene Synthesis
      - Less than 500 nt
      - 501-1000 nt
      - 1001-1500 nt
      - 1501-2000 nt
      - 2001-2500 nt
      - More than 2500 nt
  - North America Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Research and Development
      - Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
      - Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
    - Diagnostics
    - Therapeutics
      - RNAi Therapies
      - Antisense Oligonucleotide-based Therapies
      - Others
  - North America End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Biopharmaceutical and Diagnostics Companies
    - Academic and Research Institutes
    - Contract Research Organizations
  - U.S.
    - U.S. Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - U.S. Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - U.S. Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - U.S. End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Canada
    - Canada Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Canada Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Canada Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Canada End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
- Europe
  - Europe Service Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
    - Standard oligonucleotide synthesis
    - Custom oligonucleotide synthesis
    - Gene Synthesis
    - Custom gene synthesis
    - Gene library synthesis
  - Europe Length Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
      - Less than 50 nt
      - 51-100 nt
      - 101-150 nt
      - More than 150 nt
    - Gene Synthesis
      - Less than 500 nt
      - 501-1000 nt
      - 1001-1500 nt
      - 1501-2000 nt
      - 2001-2500 nt
      - More than 2500 nt
  - Europe Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Research and Development
      - Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
      - Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
    - Diagnostics
    - Therapeutics
      - RNAi Therapies
      - Antisense Oligonucleotide-based Therapies
      - Others
  - Europe End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Biopharmaceutical and Diagnostics Companies
    - Academic and Research Institutes
    - Contract Research Organizations
  - Germany
    - Germany Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Germany Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Germany Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Germany End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - UK
    - UK Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - UK Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - UK Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - UK End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - France
    - France Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - France Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - France Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - France End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Italy
    - Italy Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Italy Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Italy Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Italy End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Spain
    - Spain Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Spain Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Spain Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Spain End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Denmark
    - Denmark Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Denmark Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Denmark Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Denmark End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Sweden
    - Sweden Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Sweden Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Sweden Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Sweden End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Norway
    - Norway Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Norway Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Norway Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Norway End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
- Asia Pacific
  - Asia Pacific Service Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
    - Standard oligonucleotide synthesis
    - Custom oligonucleotide synthesis
    - Gene Synthesis
    - Custom gene synthesis
    - Gene library synthesis
  - Asia Pacific Length Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
      - Less than 50 nt
      - 51-100 nt
      - 101-150 nt
      - More than 150 nt
    - Gene Synthesis
      - Less than 500 nt
      - 501-1000 nt
      - 1001-1500 nt
      - 1501-2000 nt
      - 2001-2500 nt
      - More than 2500 nt
  - Asia Pacific Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Research and Development
      - Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
      - Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
    - Diagnostics
    - Therapeutics
      - RNAi Therapies
      - Antisense Oligonucleotide-based Therapies
      - Others
  - Asia Pacific End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Biopharmaceutical and Diagnostics Companies
    - Academic and Research Institutes
    - Contract Research Organizations
  - China
    - China Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - China Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - China Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - China End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Japan
    - Japan Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Japan Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Japan Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Japan End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - India
    - India Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - India Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - India Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - India End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - South Korea
    - South Korea Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - South Korea Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - South Korea Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - South Korea End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Australia
    - Australia Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Australia Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Australia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Australia End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Thailand
    - Thailand Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Thailand Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Thailand Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Thailand End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
- Latin America
  - Latin America Service Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
    - Standard oligonucleotide synthesis
    - Custom oligonucleotide synthesis
    - Gene Synthesis
    - Custom gene synthesis
    - Gene library synthesis
  - Latin America Length Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
      - Less than 50 nt
      - 51-100 nt
      - 101-150 nt
      - More than 150 nt
    - Gene Synthesis
      - Less than 500 nt
      - 501-1000 nt
      - 1001-1500 nt
      - 1501-2000 nt
      - 2001-2500 nt
      - More than 2500 nt
  - Latin America Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Research and Development
      - Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
      - Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
    - Diagnostics
    - Therapeutics
      - RNAi Therapies
      - Antisense Oligonucleotide-based Therapies
      - Others
  - Latin America End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Biopharmaceutical and Diagnostics Companies
    - Academic and Research Institutes
    - Contract Research Organizations
  - Brazil
    - Brazil Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Brazil Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Brazil Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Brazil End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Mexico
    - Mexico Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Mexico Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Mexico Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Mexico End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Argentina
    - Argentina Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Argentina Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Argentina Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Argentina End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
- MEA
  - MEA Service Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
    - Standard oligonucleotide synthesis
    - Custom oligonucleotide synthesis
    - Gene Synthesis
    - Custom gene synthesis
    - Gene library synthesis
  - MEA Length Outlook (Revenue, USD Million, 2018 - 2030)
    - Oligonucleotide Synthesis
      - Less than 50 nt
      - 51-100 nt
      - 101-150 nt
      - More than 150 nt
    - Gene Synthesis
      - Less than 500 nt
      - 501-1000 nt
      - 1001-1500 nt
      - 1501-2000 nt
      - 2001-2500 nt
      - More than 2500 nt
  - MEA Application Outlook (Revenue, USD Million, 2018 - 2030)
    - Research and Development
      - Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
      - Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
    - Diagnostics
    - Therapeutics
      - RNAi Therapies
      - Antisense Oligonucleotide-based Therapies
      - Others
  - MEA End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Biopharmaceutical and Diagnostics Companies
    - Academic and Research Institutes
    - Contract Research Organizations
  - South Africa
    - South Africa Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - South Africa Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - South Africa Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - South Africa End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Saudi Arabia
    - Saudi Arabia Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Saudi Arabia Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Saudi Arabia Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Saudi Arabia End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - UAE
    - UAE Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - UAE Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - UAE Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - UAE End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations
  - Kuwait
    - Kuwait Service Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
      - Standard oligonucleotide synthesis
      - Custom oligonucleotide synthesis
      - Gene Synthesis
      - Custom gene synthesis
      - Gene library synthesis
    - Kuwait Length Outlook (Revenue, USD Million, 2018 - 2030)
      - Oligonucleotide Synthesis
        
        Less than 50 nt
        
        51-100 nt
        
        101-150 nt
        
        More than 150 nt
      - Gene Synthesis
        
        Less than 500 nt
        
        501-1000 nt
        
        1001-1500 nt
        
        1501-2000 nt
        
        2001-2500 nt
        
        More than 2500 nt
    - Kuwait Application Outlook (Revenue, USD Million, 2018 - 2030)
      - Research and Development
        
        Oligonucleotide Synthesis
        
        PCR
        
        NGS
        
        CRISPR
        
        Cloning and Mutagenesis
        
        Others
        
        Gene Synthesis
        
        Synthetic Biology
        
        Vaccine Development
        
        Genetic Engineering
        
        Others
      - Diagnostics
      - Therapeutics
        
        RNAi Therapies
        
        Antisense Oligonucleotide-based Therapies
        
        Others
    - Kuwait End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Biopharmaceutical and Diagnostics Companies
      - Academic and Research Institutes
      - Contract Research Organizations

Report Content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s Five Forces analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.